Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (11649)	7/16/1998 9:29:00 PM
From: VLAD	Respond to of 23519

Alien, It's all slowly coming into place. The Pandora's box has been finally opened and now Pfizer will get a taste of their own medicine. If heart attacks are worth $65,000,000.00 then the deaths are worth at least $200,000,000.00 x 31 = $6.2 billion for the deaths. I figure there have been at least a few thousand guys on Viagra who had heart attacks. We now are looking at +10,000,000,000.00 liability issue on a product that will make less than 1/10 of that in its first year. There is no doubt in my mind that all the associated problems will eventually end up as a class action lawsuit that is going to make Dow Corning's breast implant settlement look cheap at 3.5 billion. The legal fees alone will cost Pfizer 10's of millions. Can't wait for the next chapter to unfold.

To: AlienTech who wrote (11649)	7/16/1998 9:46:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Hey alien, I think the Viagra lawsuit expains the after hour trades at 8 7/16. Some poor desperate shorts were trying to cover before tomorrow when the media starts to play with it. Would be nice to see the beginings of a nice short squeeze. I think this news may bring on a lot of institutional buying of Vivus now that the safety issues will become a forced play against Pfizer. This will help provide more juice for the money managers to wake up and see that vivus at 7.5 is dirt cheap. If the money managers believe that domestic MUSE sales will kick in especially due to safety issues they may very well buy up Vivus to at least 10 or 11 in a few days and then some deep pockets might want to start to put the squeeze on that 100+million worth of short interest which can turn into 200+million pretty fast if they don't start covering until above 13 or 14.